OMEROS CORP Class of Warrant or Right, Outstanding
OMEROS CORP (OMER) had Class of Warrant or Right, Outstanding of 0 shares as of 2023-06-30, per its 10-Q filed 2023-08-09.
Discontinued › Notes › Other Liabilities
us-gaap:ClassOfWarrantOrRightOutstanding · last filed 2023-08-09
- 2023-06-30: Class of Warrant or Right, Outstanding 0.00 shares.
- 2022-06-30: Class of Warrant or Right, Outstanding 200.00K shares.
- 2022-03-31: Class of Warrant or Right, Outstanding 200.00K shares.
- 2021-09-30: Class of Warrant or Right, Outstanding 200.00K shares.
| Period end | Class of Warrant or Right, Outstanding |
|---|---|
| 2023-06-30 | 0.00 shares 10-Q · filed 2023-08-09 |
| 2022-06-30 | 200.00K shares 10-Q · filed 2022-08-09 |
| 2022-03-31 | 200.00K shares 10-Q · filed 2022-05-10 |
| 2021-09-30 | 200.00K shares 10-Q · filed 2021-11-09 |
| 2021-06-30 | 200.00K shares 10-Q · filed 2021-08-09 |
| 2021-03-31 | 200.00K shares 10-Q · filed 2021-05-10 |
| 2015-09-30 | 1.15M shares 10-Q · filed 2015-11-09 |
| 2015-06-30 | 1.15M shares 10-Q · filed 2015-08-10 |
| 2015-03-31 | 1.16M shares 10-Q · filed 2015-05-11 |
| 2014-12-31 | 551.43K shares 10-K · filed 2015-03-16 |
| 2014-09-30 | 604.33K shares 10-Q · filed 2014-11-10 |
| 2014-06-30 | 609.02K shares 10-Q · filed 2014-08-11 |
| 2014-03-31 | 609.02K shares 10-Q · filed 2014-05-12 |
| 2013-12-31 | 609.02K shares 10-K · filed 2014-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |